Alpha2d-1 Blocking Peptides for Neuropathic Pain Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chronic neuropathic pain and epilepsy, such as gabapentinoids, have limited understanding of their molecular mechanisms, particularly regarding α2δ-1's role, and fail to fully address the rapid onset of pain hypersensitivity.
Innovation Solution
Development of isolated peptides with high sequence identity to the α2δ-1 C-terminal domain, fused with cell-penetrating peptides like TAT, which act as mimetics to block α2δ-1 binding to glutamate receptors, including NMDA and AMPA receptors, and their use in pharmaceutical compositions for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gabapentinoids are used to treat neuropathic pain, then pain relief is achieved, but the molecular mechanism of action is unclear and therapeutic effects are limited
Solution Approach 1:
The patent uses a cell-penetrating peptide (TAT) as an intermediary to deliver the alpha2d-1 blocking peptide across the cell membrane into the nervous system. This mediator enables the therapeutic peptide to reach its target site effectively, resolving the contradiction between achieving reliable pain relief and understanding the molecular mechanism by providing a clear delivery pathway and mechanism of action.
Solution Approach 2:
The therapeutic agent is segmented into two functional parts: the alpha2d-1 blocking peptide (residues 1047-1071) that provides the therapeutic effect, and the cell-penetrating TAT peptide that enables cellular uptake. This segmentation allows independent optimization of each function and clarifies the molecular mechanism of action.
2Reliability
If alpha2d-1 binding to glutamate receptors is blocked, then pain hypersensitivity is reduced, but the ability to cross cell membrane and reach target site is limited
Solution Approach 1:
The patent merges two peptide sequences into a single fusion protein: the alpha2d-1 blocking peptide (residues 1047-1071) and the cell-penetrating TAT peptide. This combination ensures both therapeutic efficacy and cellular uptake capability, resolving the contradiction between pain relief effectiveness and cell membrane penetration ability.
3Reliability
If conventional treatments are used, then some pain relief is achieved, but rapid onset of pain hypersensitivity cannot be fully addressed
Solution Approach 1:
The cell-penetrating TAT peptide enables preliminary action by facilitating rapid cellular uptake and delivery of the blocking peptide to its target site. This preliminary delivery mechanism addresses rapid-onset pain hypersensitivity before it can fully develop, while conventional treatments act too slowly to prevent rapid onset symptoms.
Data Source
AI summary
The present disclosure provides α2δ-1 C-terminal domain mimetics for the treatment of pain, epilepsy or other disorders in a subject. Further provided is an α2δ-1 C-terminal domain peptide which blocks binding of α2δ-1 to the glutamate receptors NMDAR and AMPAR.